CV6 Therapeutics Secures $9.2m to Progress Novel Cancer Drug to Phase 1a Trial
02 Nov 2022
First in ClassSmall molecular drug
Belfast, UK, 2 November 2022 – CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and inflammatory diseases, announces it has secured $9.2m to progress the company’s lead oncology asset CV6-168 into a first-in-human Phase 1a clinical trial and perform further scientific development work. Investors participating in the financing include QUBIS, the commercialization arm of Queen’s University in Belfast, Invest Northern Ireland, CoFund NI, managed by Clarendon Fund Managers, Techstart Ventures as well as US and UK-based private investors. CV6 has also received a Grant for R&D from Invest Northern Ireland* to support the Phase 1a trial.
CV6 is developing CV6-168, a novel, first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase. Cancer cell DNA uracilation by CV6-168 is aided by combination with standard cancer therapies such as thymidylate synthase (TS) inhibitors and results in uracil-based DNA damage and cell death while simultaneously stimulating the immune system to further enhance the anticancer effect. DNA uracilation is a novel therapeutic strategy that has demonstrated effectiveness and safety in pre-clinical models with no added toxicity with drug combinations. CV6-168 is set to enter a Phase 1a clinical trial in 2023 that will focus on safety, measuring how the drug is absorbed by the body, identifying optimal dosing levels and gathering initial indications of anti-cancer activity.
CV6 CEO and Founder Dr Robert Ladner said, “CV6-168 unlocks the potential of DNA uracilation as a promising new therapeutic approach to cancer treatment, with the opportunity to significantly improve outcomes for patients across multiple cancer types. Securing this financing and a grant for R&D from Invest Northern Ireland will allow us to advance CV6-168 into a first-in-human Phase 1a clinical trial, representing a key milestone for CV6.”
CV6 Therapeutics is headquartered in the Patrick G. Johnston Centre for Cancer Research at Queen’s University Belfast.
* Invest Northern Ireland’s R&D support is part financed by the European Regional Development Fund under the EU Investment for Growth and Jobs Programme 2014–2020.
Notes to Editors
About CV6 Therapeutics
CV6 Therapeutics, (NI) Ltd., is a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and inflammatory diseases.
Lead oncology drug candidate CV6-168 has successfully completed all pre-clinical development milestones. The company plans to start a first-in-human phase 1a clinical trial of CV6-168 in advanced cancers in 2023. Inflammatory disease asset CV6-1271 is in preclinical-development.
The company was originally founded in 2013 in Los Angeles, California and moved to Northern Ireland to establish the company at Queen’s University in 2015. For more information see our website here and LinkedIn here.
Media Contacts
CV6 Therapeutics
Dr Robert Ladner, CEO
+44 (0) 7500 444287
rladner@cv6t.com
Scius Communications
Katja Stout
+447789435990
katja@sciuscommunications.com
Daniel Gooch
+447747875479
daniel@sciuscommunications.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.